Видео ютуба по тегу Biocon Biologics Fy23 Assets

Biocon Biologics to Acquire Viatris Global Biosimilars Assets for upto USD 3.335 bn in stock & cash
Biocon Biologics to Acquire Viatris Global Biosimilars Assets for upto USD 3.335 bn in stock & cash
Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says
Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months
Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Kiran Mazumdar - Shaw,Executive Chairperson, Biocon & Biocon Biologics speaking on Q4 & FY23 Results
Kiran Mazumdar - Shaw,Executive Chairperson, Biocon & Biocon Biologics speaking on Q4 & FY23 Results
Biocon Limited Q4 FY23 Earnings Call
Biocon Limited Q4 FY23 Earnings Call
Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18
Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More
Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space
Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map
Biocon Earnings Call for Q4FY23 and Full Year
Biocon Earnings Call for Q4FY23 and Full Year
Biocon Biologics' and Serum Institute Life Sciences' Strategic Alliance
Biocon Biologics' and Serum Institute Life Sciences' Strategic Alliance
Biocon Limited Q3FY23 Earnings Call
Biocon Limited Q3FY23 Earnings Call
Biocon Biologics Reports Weak Q1 Numbers, With Margin Contracting QoQ | CNBC TV18
Biocon Biologics Reports Weak Q1 Numbers, With Margin Contracting QoQ | CNBC TV18
CBI arrests Biocon Biologics' AVP over allegations of bribery
CBI arrests Biocon Biologics' AVP over allegations of bribery
Insulin Aspart & Bevacizumab Have Seen Approvals Across Markets Globally: Biocon Biologics
Insulin Aspart & Bevacizumab Have Seen Approvals Across Markets Globally: Biocon Biologics
Biocon Biologics Presents #StoriesofHope: Melvin George
Biocon Biologics Presents #StoriesofHope: Melvin George
Biocon Limited Q4 FY23 Earnings Concall
Biocon Limited Q4 FY23 Earnings Concall